--- title: "Is BPC-157 legal in 2026? Three questions, three answers | Peptyn" description: "BPC-157's compounding status moved twice in 2026. What FDA Category 2 really meant, what the July 2026 advisory vote did and did not do, and where it stands." canonical: "https://peptyn.orlyn.ai/articles/bpc-157-legal-status-2026" last-updated: "2026-08-16" --- # Is BPC-157 legal in 2026? Three questions, three different answers *BPC-157's compounding status moved twice in 2026. What FDA Category 2 really meant, what the July 2026 advisory vote did and did not do, and where it stands.* Educational · Not medical advice · 18+ People searching this are usually asking three different questions at once, and the answers genuinely differ. Can a pharmacy make it? Is it an approved medicine? Will it cost an athlete a sanction? Those run on separate legal tracks, and a single search result tends to answer one and leave the other two blank. Published 15 August 2026 · 8 min read · 13 sources The confusion got worse in 2026, because the compounding question moved twice in three months and most of the coverage described the moves backwards. This article separates the three questions and shows where each one actually stands, with the primary documents linked so you can check the wording yourself. ## First, the term that everyone gets backwards: Category 2 Almost every explanation of BPC-157's status leans on the phrase "FDA Category 2," and a striking number of them treat it as a permission. It is the opposite. FDA runs an interim policy covering bulk drug substances that were nominated for the 503A bulks list but have not yet been ruled on. That policy sorts nominations into three buckets.[1] - **Category 1** is the permissive one. FDA "does not intend to take action against a compounder" for compounding with these substances while evaluation continues. - **Category 2** is the restrictive one. FDA has "identified significant safety risks relating to the use of these substances in compounding" and states it "would consider taking action against a compounder" who uses them. - **Category 3** covers nominations that arrived without enough supporting information to evaluate. So being placed in Category 2 is a warning label, not a license. A narrative review in *Current Reviews in Musculoskeletal Medicine* puts the effect plainly: in September 2023 FDA "further restricted its use by classifying it as a Category 2 bulk drug, effectively barring its inclusion in compounded medications due to concerns about safety, impurities, and insufficient human data."[8] Worth separating from all of this: the **503A bulks list** itself is a different thing from the interim categories. It is the list a compounder falls back on when a substance has no applicable USP or NF monograph and is not a component of an FDA-approved drug product, and substances get onto it through formal notice-and-comment rulemaking, not through a category assignment.[1] Nothing about the interim buckets puts a substance on that list. ## Question 1: Can a pharmacy compound it? This is the question that moved, and it moved in the permissive direction, not the restrictive one. **September 2023.** FDA placed BPC-157 in Category 2 under the 503A interim policy, the one that governs what a pharmacy may compound, citing risk of immunogenicity for certain routes of administration, complexity around peptide-related impurities and active ingredient characterization, and the fact that it had "identified no, or only limited, safety-related information for the proposed routes of administration."[2][8] **April 2026.** BPC-157 came off the Category 2 table, on a page FDA dates April 22, 2026. The mechanism matters and is usually reported wrong: FDA's page now lists BPC-157 under "Bulk drug substances nominated but withdrawn," described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators."[2] A withdrawn nomination is not an FDA finding of safety. It removes the Category 2 designation without putting anything in its place. **July 2026.** FDA convened the Pharmacy Compounding Advisory Committee on July 23 and 24. The agenda is explicit that BPC-157 free base and BPC-157 acetate were "being considered for inclusion on the 503A Bulks List," and it names the single use FDA reviewed: ulcerative colitis.[3] If that looks like it contradicts the April withdrawal, the briefing document explains why it does not. Both BPC-157 nominations, one from LDT Health Solutions on behalf of the International Peptide Society and one from Wells Pharmacy Network, had been withdrawn by the nominators, and FDA recorded against each one that it "is electing to proceed with the presentation of BPC-157-related bulk drug substances (BPC-157 (free base) and BPC-157 acetate) to the PCAC" regardless.[12] The substance went in front of the committee on the agency's own initiative, not on a live nomination. That detail is missing from essentially all of the coverage, and it is the reason the two events are not in conflict. The committee voted 8 to 6, with one abstention, to recommend BPC-157 for compounding, over the objections of FDA career scientists who said they lacked the evidence to assess safety and effectiveness.[4] NBC News reported the split by cohort: the eight most recently appointed members all voted yes, six members voted no, and one abstained.[13] The objection agency staff kept returning to was not about how well it works but about what it is, chemically, that the committee was voting on. "We've never faced a problem of, 'What is it?'" FDA's Russell Wesdyk told the panel.[13] **Where that leaves it.** The vote is a recommendation. FDA is not bound by it, and placement on the list requires a formal rulemaking cycle that trade coverage puts at roughly eight to twelve months.[4] As of this writing, BPC-157 is not on the 503A bulks list. The single most useful thing to take from this section is that three separate legal events keep getting collapsed into one: removal from Category 2, an advisory committee recommendation, and actual placement on the compoundable list following rulemaking.[4] Only the third one changes what a pharmacy may lawfully do. If you see a claim that BPC-157 is "now approved for compounding," check which of the three events it is describing. ## Question 2: Is it an approved medicine? No, and this one has not moved at all. BPC-157 has never been approved by FDA for any indication. The Department of Defense's Operation Supplement Safety notes that FDA's Approved Drugs database "does not include BPC-157 or any of its other names," and describes it as "an unapproved drug" that "cannot be legally prescribed or sold over the counter."[7] Two related points that come up constantly: **It is not a dietary ingredient.** OPSS states this directly.[7] A product marketed as a BPC-157 supplement is not a supplement in the regulatory sense, whatever the label says. **"Research use only" is a label, not a legal category that changes what a product is.** OPSS notes that products containing BPC-157 "might be labeled as 'research chemicals'" carrying statements like "Not for human consumption" or "Research use only," and advises service members to avoid them regardless.[7] The McGuire review notes the same channel from the clinical side, describing BPC-157's "continued availability via 'research chemical' websites."[8] Peptyn does not sell, source, or supply anything, and this article does not get into where products come from. The point here is narrower, which is that the phrase on the vial is not a statement about legal status. ## Question 3: Does it matter for drug testing? Yes, and this track is entirely independent of the FDA one. BPC-157 is prohibited under the World Anti-Doping Agency Prohibited List in class **S0, Non-Approved Substances**.[5][6] S0 is defined by the absence of approval rather than by any measured performance effect: it captures pharmacological substances not covered elsewhere on the list and with no current approval by any governmental regulatory health authority for human therapeutic use. It applies at all times, in and out of competition. The McGuire review dates the listing to 2022.[8] It is also on the DoD Prohibited Dietary Supplement Ingredients List.[7] The practical consequence is that a favorable compounding decision would not change the sport or military position. Those bodies key off approval status and their own lists, not off FDA's compounding policy. ## What the research actually supports Separate from all the legal questions, it is worth being precise about the evidence, because the regulatory debate keeps getting described as if the science were settled in either direction. BPC-157 is a synthetic 15 amino acid peptide, catalogued in PubChem as CID 9941957.[11] The preclinical literature is large. A 2021 *Frontiers in Pharmacology* review covers the wound healing work in detail, and it is explicit that the findings it summarizes come from rat models.[10] Human data is the gap, and the reviews do not agree on how large the gap is. The 2025 narrative review found that "only three pilot studies have examined BPC-157 in humans," covering intraarticular knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics, and concluded that "rigorous, large-scale trials are lacking" and that BPC-157 "should be considered investigational."[8] The 2021 review describes the same compound as "previously employed in ulcerative colitis and multiple sclerosis trials," which is a larger human record than the 2025 count allows for, and neither of those conditions appears among the three pilot studies the 2025 authors counted.[10][8] The discrepancy is worth sitting with, because ulcerative colitis is the one use FDA put in front of the advisory committee in July.[3] The 2025 authors also flag that every published study reports positive findings, which raises a publication bias question they name directly.[8] A 2026 *Sports Medicine* review of approved and unapproved peptides reaches a similar place: favorable results in animal models, scarce human safety data, and potential for serious harm.[9] That is the honest state of it. Not debunked, not established. ## What this means for your log None of the above tells anyone what to do. What it does change is what a record needs to capture. The identity problem FDA staff kept returning to has a practical echo. If the agency reviewing a substance says the hard part is establishing what it is, the person holding the vial has less to go on, not more, and the label is most of what they have. Note also that FDA listed BPC-157 free base and BPC-157 acetate as two distinct bulk drug substances, so "BPC-157" on its own is an incomplete description of what was in the vial.[3] So the useful fields are the boring ones: exactly what the label said, including the salt form if it is stated at all, who prepared it and under what authority, the lot or batch number if there is one, the date, and what you noticed afterward. Regulatory status shifts, and this one shifted twice in three months. A record written down at the time survives those shifts. A memory of what you were told does not. Peptyn's compound library exists for exactly this. BPC-157 has an entry not because Peptyn recommends it, but because people log it, and an entry that states what the published literature says and links to the sources is more useful than one that does not exist. The app records what you entered. It does not calculate anything, it does not tell you what to take, and it does not tell you where to get it. ## What to ask a prescriber If you are already taking a BPC-157 product, the questions worth asking are about provenance and authority: what exactly is in it, who made it, and under what authority it was prepared. If you are considering it, a licensed healthcare provider is the right person to have that conversation with, because they can weigh your individual situation against a literature base that both of the recent reviews cited here describe as thin in humans. A written record of what you actually took and when is what makes that conversation specific instead of approximate. ## References 1. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. *U.S. Food and Drug Administration*. 2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. *U.S. Food and Drug Administration*. 3. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. *U.S. Food and Drug Administration*. 4. FDA Panel Votes to Loosen Restrictions for Four Peptides. *Pharmaceutical Executive*, July 24, 2026. 5. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide. *U.S. Anti-Doping Agency*. 6. The Prohibited List. *World Anti-Doping Agency*. 7. BPC-157: A Prohibited Peptide and an Unapproved Drug Found in Health and Wellness Products. *Operation Supplement Safety, U.S. Department of Defense*. 8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. *Curr Rev Musculoskelet Med*. 2025;18(12):611-619. 9. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. *Sports Med*. 2026;56(8):1921-1935. 10. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. *Front Pharmacol*. 2021;12:627533. 11. BPC 157, PubChem Compound Summary (CID 9941957). *PubChem*. 12. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 (Introduction). *U.S. Food and Drug Administration*. 13. FDA panel recommends easing some peptide restrictions despite disapproval from scientists. *NBC News*, July 23, 2026. ## Keep reading - [Retatrutide is not approved. What that means.](https://peptyn.orlyn.ai/articles/retatrutide-approval-status-2026) What investigational status is as a legal category, why a planned filing is not an approval date, and where the trials stand. - [The glossary that will not do your math](https://peptyn.orlyn.ai/articles/peptide-glossary) Plain definitions from lyophilized to 503A, with sources. It defines every term and stops where the arithmetic starts. - [Compounded GLP-1s: the 2026 timeline](https://peptyn.orlyn.ai/articles/compounded-glp1-2026-regulatory-changes) Every date traced to an FDA or Federal Register document, and why your own log is what carries across a formulation change. This article is educational. It does not recommend doses, schedules, or products, and it is not medical advice. Every factual claim above is linked to its source. Questions about your own protocol belong with the prescriber who wrote it. --- Source: